Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700

M I N U T E S

Regular Board Meeting

Wednesday, May 6, 2026
Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809

TABLE OF CONTENTS

The Louisiana Board of Pharmacy (the “Board”) convened a regular meeting on **Wednesday, May 6, 2026** at the Louisiana Board of Pharmacy located at 3388 Brentwood Drive in Baton Rouge, Louisiana 70809. The meeting was held pursuant to public notice, each member received notice, and public notice was properly posted.

CALL TO ORDER

Mr. Richard M. Indovina, Jr., President, called the meeting to order at 9:33 a.m.

INVOCATION & PLEDGE OF ALLEGIANCE

Dr. J. Robert Cloud delivered the invocation and Mr. Don L. Resweber led the group in the Pledge of Allegiance.

QUORUM CALL

Mr. Richard M. Indovina, Jr., called upon Mr. David A. Darce, Secretary, to call the roll of members to establish a quorum.

Members Present:

- Dr. J. Robert Cloud, PharmD
- Mr. David A. Darce
- Ms. Jacqueline L. Hall
- Mr. Richard M. Indovina, Jr.
- Mr. W. Charles Jones
- Mr. Kevin LaGrange
- Mr. Richard Mannino
- Mr. Marty R. McKay
- Ms. Chris B. Melancon
- Mr. J. Troy Menard
- Mr. Anthony G. Mercante
- Mr. Robert A. “Butch” Ray
- Mr. Don L. Resweber
- Mr. Richard A. “Andy” Soileau
- Dr. Raymond J. Strong, PharmD

Members Absent:

- Dr. David G. Collins, PharmD
- Ms. Jennifer E. Dupree

Staff Present:

- Mr. M. Joseph Fontenot Jr., Executive Director
- Mr. Carlos M. Finalet, III, General Counsel
- Ms. M. Danielle Hartzog, Administrative Program Specialist
- Ms. Kelley L. Villeneuve, Office Manager
- Dr. Jordan T. Bergeaux, PharmD, Pharmacist – Compliance Officer
- Mr. Benjamin S. Whaley, Pharmacist – Chief Compliance Officer

Guests:

- Dr. Shardae Pierre, PharmD – Galleria Medical Pharmacy
- Dr. Valarie Melancon, PharmD – CVS
- Ms. Brandi Armand – Louisiana Pharmacists Association (LPA)
- Dr. Michael B. Cockerham, PharmD – LPA / University of Louisiana Monroe
- Mr. Jesse Vidrine – Vidrine Pharmaceutical Group (VPG)
- Mr. Chad T. Bodin – Pharmacist
- Dr. Jacqueline Esqueda, PharmD – Eagle Analytical Services
- Dr. Ross Caputo, Ph.D. – Eagle Analytical Services

- Dr. Jay P. Patel, Ph.D. – Eagle Analytical Services
- Mr. Malcolm J. Broussard – Hygeia Solutions
- Ms. Kim Boasso – PharmCare of LA
- Ms. Jessica Elliot – Louisiana Association of Retail Pharmacies (LARP)
- Ms. Sarah Perkins – Breazeale, Sachse & Wilson (BSW)
- Ms. Rachel Guarisco – Galleria Medical Pharmacy

Secretary Darce certified 15 members were present, constituting a quorum for the conduct of official business.

CALL FOR ADDITIONAL AGENDA ITEMS & ADOPTION OF AGENDA

Mr. Indovina asked if there were any additional agenda items to be added; none were requested. Without objection, the members adopted the posted agenda dated May 5, 2026. There were no objections to Mr. Indovina's request for authority to re-order the agenda should the President determine it appropriate to do so.

CONSIDERATION OF DRAFT MINUTES FROM PREVIOUS MEETING

Mr. Indovina reminded the members they had received the draft minutes from the regular Board meeting held on February 25, 2026. With no objections, he waived the reading of the draft minutes. With no requests for amendments or corrections, and with no objection, Mr. Indovina declared the minutes were approved as presented.

REPORT ON ACTION ITEMS

Mr. Indovina called upon Mr. Fontenot to present the report. Mr. Fontenot referred the members to the information provided in the meeting materials and advised that Dr. Cloud will present this information later in the meeting as part of his committee report.

CONFIRMATION OF ACTS

Pursuant to Mr. Indovina's declaration that the officers, members and committees, and executive director had attended to the business of the Board since their last meeting in accordance with policies and procedures previously approved by the Board, Mr. Mernard moved:

> ***Resolved****, that the decisions made and the actions taken by the Board officers, members and committees, and executive director in the general conduct and transactions of Board business since February 25, 2026 are approved, adopted, and ratified by the entire Board.*

Mr. Mercante seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

OPPORTUNITY FOR PUBLIC COMMENT

Mr. Indovina reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present; none were offered.

STATEMENT OF PURPOSE

Mr. Indovina reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their legislative mandate in mind as they considered all the matters before them.

SPECIAL ORDERS OF THE DAY

Mr. Indovina informed the members and guests that the terms of five Board members were scheduled to conclude on June 30, 2026. He then presented Mr. David Darce, Ms. Jacqeline Hall, Mr. W. Charles Jones, Mr. Marty McKay, and Mr. Anthony Mercante, each with a *Distinguished Service Award*, highlighting their dedicated service to the state of Louisiana as members of the Board.

Mr. Indovina then announced that he would reorder the posted agenda to consider agenda item *I.10 Consideration of ScanRDI Sterility Testing Method*.

EXECUTIVE COMMITTEE REPORT

Consideration of ScanRDI Sterility Testing Method

Mr. Indovina invited guests present to speak on ScanRDI Sterility Testing. Dr. Jacqueline Esqueda, Dr. Jay Patel, and Dr. Ross Caputo from Eagle Analytical Services, Jesse Vidrine from VPG, and Rachel Guarisco from Galleria Medical Pharmacy all introduced themselves in support of ScanRDI Sterility Testing.

Mr. Indovina then explained that one of the Board's Compliance Officers attended a national training course which included a presentation by a former expert committee member for the USP Compounding Committee. As part of the training, the Compliance Officer learned that the ScanRDI Sterility testing method was not in compliance with USP 797 requirements. Eagle Analytical Services contacted the Board's Executive Director regarding their ScanRDI method. Our Executive Director restated the Board's long-standing position of strict adherence to USP, with no exceptions, and requested documentation supporting compliance.

The committee reviewed the matter and decided to refer to the full Board with no recommendation.

Following comments and testimony by the public and extensive discussion, Mr. McKay moved:

> ***Resolved**, ScanRDI® sterility testing method is a destructive method whereby a failed sterility test cannot be used for identification of the microorganism(s) as required by USP 797. Therefore, ScanRDI® is not compliant with USP 797.*
>
> *Beginning on May 6, 2026, if ScanRDI® is utilized by adhering to the following process and is addressed as such in the pharmacy's policies & procedures, the Board will exercise enforcement discretion and take no action regarding this aspect of USP 797 compliance:*
>
> - *The required number of units of the compounded preparation are sent to the contracted testing laboratory for testing, and the remaining compounded preparation is held by the pharmacy and not dispensed until sterility is confirmed.*
> - *Once sterility is confirmed, the compounded sterile preparation may then be released for dispensing.*
> - *If testing reveals a lack of sterility, the remaining compounded preparations are not dispensed, and a sufficient number of additional units are sent to the testing laboratory for identification of the microorganism(s) that may be present in the remaining units.*

Mr. Resweber seconded the motion. With more discussion from Board members and one public comment, the motion was unanimously approved.

Mr. Indovina declared a recess at 10:39 a.m. with the meeting reconvening at 10:55 a.m.

FINANCE COMMITTEE REPORT

Mr. Indovina recognized Mr. Soileau to deliver the committee report. Mr. Soileau reported the committee has not met since the previous Board meeting and the next meeting is tentatively scheduled for August 11, 2026. He further explained that during the August Board meeting, the committee will consider the Board's "Compiled Financial Statements for Fiscal Year 2025-2026" and provide a recommendation for consideration.

Mr. Soileau concluded his report by recognizing the other members of the committee: Dr. Collins, Mr. Jones, Ms. Melancon and Mr. Ray.

APPLICATION REVIEW COMMITTEE REPORT

Mr. Indovina recognized Ms. Melancon to deliver the committee report. Ms. Melancon reported that the committee met the previous day to consider one application for a nonresident pharmacy permit. After discussions, the committee deferred consideration to acquire additional relevant information regarding the applicant. The committee had no recommendations for the Board's consideration.

Ms. Melancon concluded her report by recognizing the other members of the committee: Dr. Collins, Mr. Darce, Mr. Mannino and Mr. Ray.

RECIPROCITY COMMITTEE REPORT

Mr. Indovina called upon Mr. Mannino for the committee report. Mr. Mannino reported that during the first quarter of the calendar year, 127 applicants were evaluated by staff and found to be eligible for licensure by reciprocity. No one required an interview by the committee. In conformance with the policies and procedures previously approved by the Board, their applications were approved and then their licenses were issued by the staff. A list of the pharmacists who were licensed by reciprocity in the first quarter was included in the meeting material.

Mr. Mannino concluded the report by recognizing the other committee members: Mr. Darce, Mr. LaGrange, Mr. Mercante, Mr. Ray, and Mr. Soileau.

VIOLATIONS COMMITTEE REPORT

Mr. Indovina called upon Mr. Mercante for the committee report. Mr. Mercante reported the committee met on March 17, 2026 to consider two cases on their agenda. Following their interviews and subsequent deliberations, the committee developed recommendations for the Board's consideration. Mr. Mercante directed the members to copies of those proposals in their meeting materials and then proceeded to present the following cases:

> **Kristin Marie Picou (PST.022095):** Mr. Mercante moved to approve the proposed voluntary consent agreement. Ms. Hall seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved. For diversion of controlled substances which was self-reported, the Board suspended her license for 6 months beginning on May 6, 2026, and terminating on November 6, 2026, suspended the suspension, then placed the license on probation for the period of suspension, subject to a condition of probation; and further, assessed administrative and investigative costs.
>
> **My Pharmacy of Monroe, LLC dba My Pharmacy of Monroe (Monroe, LA) (PHY.008141):** Mr. Mercante moved to approve the proposed voluntary consent agreement. Ms. Hall seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved. For its failure to designate a new pharmacist-in-charge within 10 days of the departure of the prior pharmacist-in-charge, the Board assessed a fine of $2,500 plus administrative and investigative costs.

Mr. Mercante concluded his report by announcing the next scheduled informal conference is scheduled for June 10-11, 2026. He also recognized Dr. Cloud, Ms. Dupree, Ms. Hall, and Mr. Menard for their service on the committee.

IMPAIRMENT COMMITTEE REPORT

Mr. Indovina recognized Ms. Hall to deliver the committee report. Ms. Hall reported that the committee convened the previous day to consider one referral from staff. The committee did not have a case requiring Board consideration.

Ms. Hall then advised members that the current *Roster of Approved Addictionists* was provided in their meeting material. The committee has reviewed and recommends approval of the roster. Ms. Hall moved:

> ***Resolved**, to approve the updated Roster of Approved Addictionists.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall concluded her report by recognizing fellow committee members: Dr. Collins, Mr. Darce, Mr. Menard, Mr. Resweber and Dr. Strong.

REINSTATEMENT COMMITTEE REPORT

Mr. Indovina recognized Dr. Strong for the committee report. Dr. Strong reported the committee convened the previous day. After conducting an interview and engaging in subsequent deliberations, the committee developed one recommendation for the Board's consideration. He then proceeded to present the following case:

> **John David Hall (PST.014820):** Dr. Strong moved to approve the request for reinstatement of the lapsed pharmacist license without restriction. Dr. Cloud seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Dr. Strong concluded his report by recognizing fellow committee members: Ms. Dupree, Mr. Jones, Mr. LaGrange, Mr. Mannino, and Mr. Mercante.

TRIPARTITE COMMITTEE REPORT

Mr. Indovina recognized Mr. Resweber for the committee report. Mr. Resweber reported the committee has not met since February and plans to meet in February 2027.

Mr. Resweber concluded his report by recognizing fellow committee members: Ms. Dupree, Mr. Jones, Mr. LaGrange, Mr. Menard, and Dr. Strong.

REGULATION REVISION COMMITTEE REPORT

Mr. Indovina called upon Dr. Cloud for the committee report. Dr. Cloud reported that the committee has not met since the last report. However, he provided updates on the following regulatory projects and legislative proposal.

From the August 20, 2025 Board meeting, the Board approved:

- Regulatory Project 2025-07 – Prescription Drug Delivery
- Regulatory Project 2025-08 – Centralized Prescription Dispensing
- Regulatory Project 2025-09 – PMP Record Retention.

The final rules for all three projects were published in the *Louisiana Register* on March 20, 2026, and became effective immediately.

From the November 19, 2025 Board meeting, the Board approved:

- Regulatory Project 2026-01 – Controlled Dangerous Substances
- Regulatory Project 2026-02 – Remote Access by a Pharmacy Technician
- Regulatory Project 2026-03 – Community Pharmacy
- Regulatory Project 2026-04 – Institutional Pharmacy

The Notices of Intent for all 4 projects were published in the *Louisiana Register* on January 20, 2026 and a Public Hearing was held on February 26, 2026 to receive comments and testimony on the projects. No public comments or testimony were received. The summary reports for all four projects were submitted to the Joint Legislative Oversight Committee on Health & Welfare on March 13, 2026. No inquiries or notice from the legislature were received. As soon as we receive approvals from the Occupational Licensing Review Program, staff will proceed with publication of the final Rules.

From the February 25, 2026 Board meeting, the Board approved:

- Legislative Proposal 2026-A – CDS Schedules Update

HB152 by Representative Shane Mack passed the Senate and House without amendments and will be sent to the Governor for his signature.

- Regulatory Project 2026-05 – Off-Site Services
- Regulatory Project 2026-06 – Advertising
- Regulatory Project 2026-07 – Pharmacy Interns Professional Experience
- Regulatory Project 2025-454 – Pharmacists (formerly referred to as Solicitation of Comments)

The fiscal and economic impact statements for all four projects were submitted to the Legislative Fiscal Office for their review and approval. Once approved, staff will proceed with submission of the Notices of Intent for publication.

Dr. Cloud concluded his report by acknowledging the contributions of fellow committee members: Mr. Darce, Ms. Hall, Mr. McKay, Ms. Melancon, Mr. Menard, and Mr. Soileau.

EXECUTIVE COMMITTEE REPORT

Mr. Indovina reported that the committee met the previous day to consider the items on its posted agenda. He noted that Ms. Hall was prepared to present motions on behalf of the committee and reminded members that the related documents were included in the Board meeting materials.

Consideration of Continuing Approval of Loss Prevention Manual

Mr. Indovina stated, the committee reviewed the Board's *Loss Prevention Manual* and voted to recommend continuing approval. Ms. Hall moved:

> ***Resolved,*** *to renew the approval of the Loss Prevention Manual for Fiscal Year 2026-2027.*

Mr. Mercante seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Consideration of Continuing Approval of Updated Policy & Procedure Manual

Mr. Indovina explained that staff updated the *Policy & Procedure Manual* by incorporating all the revisions authorized by the Board since the May 7, 2025 meeting and the committee voted to recommend continuing approval of the updated manual. Ms. Hall moved:

> ***Resolved,*** *to renew the approval of the updated Policy & Procedure Manual for Fiscal Year 2026-2027.*

Dr. Cloud seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Consideration of Continuing Approval of Updated Roster of Board-Approved Colleges of Pharmacy

Mr. Indovina explained that staff updated the roster based on the most recent status information available from ACPE. The committee voted to recommend continuing approval of the updated roster. Ms. Hall moved:

> ***Resolved,*** *to renew the approval of the updated Roster of Board-Approved Colleges of Pharmacy for Fiscal Year 2026-2027.*

Dr. Cloud seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Consideration of Continuing Approval of Updated Roster of Board-Approved Pharmacy Technician Training Programs

Mr. Indovina explained that staff updated the roster to reflect the current accreditation status of programs. The committee voted to recommend continuing approval of the updated roster. Ms. Hall moved:

> ***Resolved,*** *to renew the approval of the updated Roster of Board-Approved Pharmacy Technician Training Programs for Fiscal Year 2026-2027.*

Dr. Cloud seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Consideration of Continuing Approval of Credentialing Examinations

Mr. Indovina stated, the committee voted to recommend continuing approval of the current credentialing examination administrators and exams. Ms. Hall moved:

> ***Resolved,*** *to renew our approval of the National Association of Boards of Pharmacy (NABP) as administrator of the pharmacist licensure examinations for Fiscal Year 2026-2027, including the North American Pharmacist Licensure Examination (NAPLEX), the Multistate Pharmacy Jurisprudence Examination (MPJE), and the Foreign Pharmacy Graduate Equivalency Examination (FPGEE).*

Dr. Cloud seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to renew our approval of the Pharmacy Technician Certification Examination (PTCE) administered by the Pharmacy Technician Certification Board (PTCB) for Fiscal Year 2026-2027.*

Dr. Cloud seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to renew our approval of the Examination for Certification of Pharmacy Technicians (ExCPT) administered by National Healthcareer Association (NHA) for Fiscal Year 2026-2027.*

Dr. Cloud seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Consideration of Proposed Resolutions for Professional Legal Services

Mr. Indovina explained, the attorney general requires all state agencies contracting for professional legal services to certify through resolution that such contracts do not include contingency fees. A copy of the resolution was included in the meeting materials. The committee voted to recommend approval of the proposed resolutions for Ms. Celia R. Cangelosi as well as the legal firm of Shows, Cali & Walsh.

Ms. Hall moved:

> ***Resolved,*** *to approve the Proposed Resolution for Professional Legal Services for Ms. Celia R. Cangelosi for Fiscal Year 2026-2027.*

Mr. Resweber seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall then moved:

> ***Resolved,*** *to approve the Proposed Resolution for Professional Legal Services for Shows, Cali & Walsh for Fiscal Year 2026-2027.*

Mr. Resweber seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Consideration of Annual Renewal of Contracts & Agreements

Mr. Indovina reported, with respect to contracts and agreements, that staff reviewed the performance objectives of each contract and determined that the contractors have met their obligations to the Board, and further, recommends the renewal of those contracts. Staff prepared a summary of those contracts showing the financial terms of those agreements. That summary document was provided in the meeting materials. In addition to the two contracts for legal services, there are other contracts for accounting services, the Prescription Monitoring Program, and for other aspects of Board operations. The committee voted to recommend approval of these contracts. Ms. Hall moved:

> ***Resolved****, to approve the proposed contract for professional legal services with Ms. Celia R. Cangelosi, at the stipulated rate, in an amount not to exceed $125,000 for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed contract for professional legal services with Shows, Cali & Walsh, LLP, at the stipulated rates, in an amount not to exceed $50,000 for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed contract for professional accounting services with Champagne & Company, LLC, Certified Public Accountants, at the stipulated rates, in an amount not to exceed $40,000 for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed contract for the operation of the Louisiana Prescription Monitoring Program with Bamboo Health, Inc. at the stipulated rate, in an amount not to exceed $215,000 for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed contract for the Prescription Monitoring Program Gateway with Bamboo Health, Inc. at the stipulated rate, in an amount not to exceed $600,000 for Fiscal Year 2026-2027 contingent upon receipt of grant funds.*

Ms. Melancon seconded the motion. With one question from a member and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed contract with Tyler Technologies to maintain, update, and provide the hosting services for the Board's eLicense information system, at the stipulated rate, in an amount not to exceed $150,000 for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed renewal of the interagency agreement with the Louisiana Department of Justice for participation in the Occupational Licensing Review Program, at the stipulated rate, in an amount not to exceed $45,000 for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed contract with Covalent Logic for website hosting services and updates, at the stipulated rate, in an amount not to exceed $8,000 for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed agreement for debt collection services with the Louisiana Department of Revenue, Office of Debt Recovery, at the stipulated rate, for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With one question from a member and no public comments, the motion was unanimously approved.

Ms. Hall moved:

> ***Resolved,*** *to approve the proposed agreement for the publication of the Board's Newsletter by the NABP Foundation in an amount not to exceed $4,000 for Fiscal Year 2026-2027.*

Ms. Melancon seconded the motion. With one question and a brief discussion from Board members and no public comments, the motion was unanimously approved.

Mr. Indovina then advised members that the next item is not included in the summary document for contracts and agreements. This motion will authorize the Board to receive grant funds from the Louisiana Department of Health to cover the expenses of the PMP Gateway and other services.

Ms. Hall then moved:

> ***Resolved,*** *to approve the proposed agreement with the Louisiana Department of Health – Office of Public Health – Bureau of Community Preparedness for the receipt of grant funds to cover the expenses of the PMP Gateway® through Bamboo Health and other services for Fiscal Year 2026-2027.*

Mr. McKay seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Proposed Revision PPM.II.D.2.a – Record Retention Schedule, Draft #1

Mr. Indovina explained that the Louisiana Secretary of State's office requires agencies to generate and maintain a record retention schedule and further mandates that each schedule be renewed every five years. The Board's current schedule expired on March 1, 2026. The schedule was submitted for renewal and ultimately returned with several recommended changes summarized in the memorandum included in the meeting materials. Ms. Hall then moved:

> ***Resolved****, to approve proposed revision PPM.II.D.2.a – Record Retention Schedule Draft #1, and to authorize the Board President to approve acceptable amendments that may become necessary in discussions with the Secretary of State's office.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Proposed New Policy PPM.I.A.38 – Changes Pharmacists May Make to Schedule II Paper Prescriptions, Draft #1

Mr. Indovina explained that Board staff anticipates completion of Regulatory Project 2026-01 – Controlled Dangerous Substances by June 20, 2026. The project seeks to streamline the regulatory framework by adopting federal regulations by reference, consolidating any provisions that differ from the Code of Federal Regulations (CFR) into Section 2713, and repealing all remaining sections containing redundant requirements. The current rule regarding completion of a Schedule II prescription will be repealed as part of the regulatory project.

On October 18, 2022, the DEA issued a guidance document titled – *Changes Pharmacists May Make to Schedule II Prescriptions*. The guidance document will remain in effect until the DEA codifies new regulations, or until the guidance is modified or withdrawn. The guidance states pharmacists should adhere to state regulations or policy regarding those changes that a pharmacist may make to a schedule II prescription after oral consultation with the prescriber.

In anticipation of the repeal of the Board's rule prior to DEA codifying new regulations addressing this matter, staff prepared a policy which adopts the current rule, and it would remain active until DEA codifies regulations, or until the DEA guidance is modified or withdrawn, or the policy is rescinded by the Board. Ms. Hall then moved:

> ***Resolved****, to approve proposed new policy PPM.I.A.38 – Changes Pharmacists May Make to Schedule II Paper Prescriptions, Draft #1.*

Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Consideration of Gates Healthcare Associates Licensing Inspection Services

Mr. Indovina reported that the Board office was contacted by a couple of nonresident pharmacies requesting that the Board consider acceptance of the Gates Healthcare Associates Licensing Inspection Services for their USP 795 and USP 797 nonresident pharmacy inspections. He reminded the members; the Board currently accepts inspections for nonresident pharmacies from NABP and ACHC.

The committee reviewed the materials provided but determined more information was required, so the matter was deferred to the next meeting.

Consideration of Licensing Information System Upgrade

Mr. Indovina stated, as reported over the past year, Board staff have been evaluating new licensing information system options to replace our ageing system. After a thorough review of possible solutions, staff identified two systems that currently met the Board's needs - inLumon and GL Solutions. Quotes were received from the two vendors, and the less expensive quote is the preferred system identified by staff. Ms. Hall then moved:

> ***Resolved****, to approve the contract with SHI International Corporation for the procurement of inLumon regulatory software. inLumon will develop, implement, maintain, and host the Board's new licensing information system at a cost not to exceed $650,000 for implementation and $85,000 in annual recurring costs for Year One of Fiscal Year 2026-2027, contingent upon state approval.*

Mr. McKay seconded the motion. After discussion, comments, and questions from Board members and no public comments, the motion was unanimously approved.

Board Office Administrative Operations Update

Mr. Indovina asked Mr. Fontenot to provide an update. Mr. Fontenot reported that the sale of the property in Towne Center is complete. He also informed members that the appearance of the Board website has changed in a manner intended to ensure compliance with ADA requirements. Finally, he reported that the previously approved office updates and renovations are in the works with Office of Facility Planning with intentions of starting these projects as soon as possible. There were no comments or questions from the members.

Legislative Update – 2026 Regular Session

Mr. Indovina asked Mr. Fontenot to provide an update. Mr. Fontenot reported that HB152 by Representative Shane Mack passed the Senate and House without amendments and will be sent to the Governor for his signature. There were no other Board sponsored bills. There were no comments or questions from the members.

Notice of Exceptions Report

Mr. Indovina explained, in accordance with Board policy, the Board President is authorized to review and respond to requests for exceptions to laws, rules, and policies between Board meetings. The policy also authorizes the Executive Director, with the concurrence of the Board President, to issue Special Work Permits and approve dual PIC privileges, with notice provided to the Board at its next meeting. The committee reviewed the current *Exceptions Report*, which was available in the meeting materials, and is now presented to the full Board. No action is required. There were no comments or questions from the members.

Mr. Indovina concluded his report by acknowledging the contributions of fellow committee members: Ms. Hall, Mr. Resweber, Dr. Cloud, and Mr. Darce.

REPORT OF GENERAL COUNSEL

Mr. Indovina recognized Mr. Finalet to present his report. Mr. Finalet then submitted the following proposed voluntary staff consent agreements for the Board's consideration:

LaToya Dominique Batiste (PST.020797): Ms. Hall moved to accept the proposed voluntary consent agreement. Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved. For failing to report an adverse action as part of the pharmacist license renewal application for the year 2026, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of $1,000 plus administrative costs.

Chrysalis Group, LLC dba Manor Pharmacy II (Katy, TX) (PHY.009007): Ms. Hall moved to accept the proposed voluntary consent agreement. Ms. Melancon seconded the motion. With one question from a member and no public comments, the motion was unanimously approved. For dispensing 15 prescriptions into Louisiana from January 1 to April 14, 2026, with an expired Louisiana nonresident pharmacy permit, the Board assessed a fine of $5,000 plus administrative costs.

Darcell Nicole Duhon (CPT.017860): Ms. Hall moved to accept the proposed voluntary consent agreement. Ms. Melancon seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved. For diversion of controlled substances, the Board revoked her credential; and further, prohibited her from applying or reapplying to practice or assist in the practice of pharmacy.

Mr. Finalet then indicated completion of his report.

REPORT OF THE EXECUTIVE DIRECTOR

Mr. Indovina called upon Mr. Fontenot to present his report. Mr. Fontenot referred members to the quarterly report of the Louisiana Prescription Monitoring Program (PMP) included in the meeting materials. There were no questions or comments from the members.

Mr. Fontenot then directed the members to review requests from 15 pharmacies seeking a waiver from the duty to submit zero prescription transaction reports to the PMP. Dr. Cloud then moved:

> ***Resolved****, to authorize the issuance of full PMP reporting waivers to the following permits once they have executed the standard consent agreement for that purpose:*

- PHY.009108-NR Bluebird
- PHY.009114-NR Buderer Drug Company
- PHY.009116-NR CPS Solutions, LLC
- PHY.009093-NR Gifthealth Pharmacy AZ
- PHY.009107-NR Glendale Pharmacy, LLC
- PHY.009134-NR Green Stone Rx
- PHY.009137-NR Health Care Medical Infusion Specialties
- PHY.009081-NR Omnicell Specialty Pharmacy Services, Inc.
- PHY.009111-NR Optime Care Inc.
- PHY.009110-IR Pharma Fusion LLC
- PHY.009100-NRN PharmaLogic Cincinnati, LLC

- PHY.009104-NR Santa Rosa Pharmacy
- PHY.009032-NR Shady Grove Pharmacy
- PHY.009080-SAT Slidell Regional Cancer Center
- PHY.009113-NR Veterinary Pharmaceutical Solutions

Mr. McKay seconded the motion. With no discussion from Board members and no public comments, the motion was unanimously approved.

Mr. Fontenot then indicated completion of his report.

NEW AGENDA ITEMS ADDED DURING MEETING

There were no new agenda items added during the meeting.

ANNOUNCEMENTS

Mr. Indovina advised the members that their announcements were included in their meeting material.

ADJOURN

Having completed the tasks listed on the posted agenda, with no further business pending before the Board and without objection, Mr. Indovina adjourned the meeting at 11:37 a.m.

Minutes prepared by Joe Fontenot and then approved as presented during the subsequent meeting on August 12, 2026.

____

David A. Darce
Secretary